Ishimori Shotaro, Okada Shinichiro, Yamagata Shunsuke, Satoh Shoichi
Dept. of Thoracic Medicine, Kamaishi Municipal Hospital.
Gan To Kagaku Ryoho. 2005 Mar;32(3):345-9.
We investigated the effectiveness and complications of intrathoracic infusion with a combination of cisplatin, OK-432, and minocycline for malignant pleural effusion. All patients were hospitalized with chest tube drainage of pleural effusion until the daily drainage volume was less than 100 ml. Twenty-five mg of minocycline, 1 to 3 KE of OK-432, and 5 to 10 mg of cisplatin were instilled into the pleural space. The administration was repeated until drainage effusion disappeared. Therapeutic effect was evaluated according to the following criteria: (1) excellent, no fluid reaccumulation for at least 4 weeks as determined by chest radiogram and clinical evaluation; (2) effective, fluid reaccumulation less than 50% of original effusion with no need of thoracentesis for symptomatic relief within 4 weeks after treatment; and (3) failure, reaccumulation of more than 50% of the original effusion requiring thoracentesis to relieve symptoms within 4 weeks of treatment. Twelve patients with malignant effusion received the combination treatment; 11 patients had primary lung cancer and one had metastatic lung tumor from cancer of the rectum. In all cases, the histology or cytology revealed adenocarcinoma. Eleven of the 12 patients had an excellent response with relief of clinical symptoms. The remaining case failed to show any improvement. Complications such as local pain, fever, nausea, and vomiting were mild and transient. We conclude that combination administration of low-dose minocycline, OK-432, and cisplatin into the thoracic cavity for malignant effusion is an effective alternative treatment with the potential for improvement of the general condition and reduced morbidity.
我们研究了顺铂、溶链菌制剂OK-432和米诺环素联合胸腔内注入治疗恶性胸腔积液的有效性及并发症。所有患者均住院接受胸腔闭式引流,直至每日引流量少于100ml。将25mg米诺环素、1至3KE OK-432和5至10mg顺铂注入胸腔。重复给药直至引流液消失。根据以下标准评估治疗效果:(1)优:胸部X线片及临床评估显示至少4周无液体再积聚;(2)有效:治疗后4周内液体再积聚少于原积液的50%,且无需胸腔穿刺缓解症状;(3)无效:治疗后4周内原积液再积聚超过50%,需要胸腔穿刺缓解症状。12例恶性胸腔积液患者接受了联合治疗;11例为原发性肺癌,1例为直肠癌肺转移瘤。所有病例的组织学或细胞学检查均显示为腺癌。12例患者中有11例反应良好,临床症状缓解。其余1例未见任何改善。局部疼痛、发热、恶心和呕吐等并发症轻微且短暂。我们得出结论,低剂量米诺环素、OK-432和顺铂联合胸腔内给药治疗恶性胸腔积液是一种有效的替代治疗方法,有可能改善一般状况并降低发病率。